Craft
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
WuXi Biologics revenue increased from ¥4 billion in 2019 to ¥5.6 billion in 2020, a (40.9%) increase.

Annual Revenue (¥)

WuXi Biologics revenue was ¥5.61 b in FY, 2020 which is a (40.9%) year over year increase from the previous period.

FY, 2017FY, 2018FY, 2019FY, 2020
Revenue¥1.62 b¥2.53 b¥3.98 b¥5.61 b
Growth56.56%57.18%40.88%

Annual Growth Rate (%)

Revenue Breakdown

Geographic Segment

WuXi Biologics revenue breakdown by geographic segment: 43.9% from PRC, 44.2% from North America, 8.0% from Europe and 4.0% from Other

FY, 2018FY, 2019FY, 2017
Post-IND Services1.08 b2.15 b569.6 m
Pre-IND Services1.45 b1.81 b1.05 b
Other 23.3 m
FY, 2020FY, 2018FY, 2019FY, 2017
United States1.28 b900.64 m
Europe446.6 m171.66 m311.46 m65.31 m
Rest of the World222.51 m98.83 m127.1 m100.85 m
China980.02 m1.41 b552.04 m
North America2.48 b2.14 b
PRC2.46 b

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Footer menu